Whitehawk Therapeutics, Inc. (WHWK) - Net Assets
Based on the latest financial reports, Whitehawk Therapeutics, Inc. (WHWK) has net assets worth $157.17 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($167.02 Million) and total liabilities ($9.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check WHWK asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $157.17 Million |
| % of Total Assets | 94.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 28.14 |
Whitehawk Therapeutics, Inc. - Net Assets Trend (2019–2024)
This chart illustrates how Whitehawk Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore WHWK asset base for the complete picture of this company's asset base.
Annual Net Assets for Whitehawk Therapeutics, Inc. (2019–2024)
The table below shows the annual net assets of Whitehawk Therapeutics, Inc. from 2019 to 2024. For live valuation and market cap data, see how much is Whitehawk Therapeutics, Inc. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $52.48 Million | -50.11% |
| 2023-12-31 | $105.19 Million | -33.58% |
| 2022-12-31 | $158.38 Million | +16.11% |
| 2021-12-31 | $136.41 Million | +1197.22% |
| 2020-12-31 | $-12.43 Million | -36.71% |
| 2019-12-31 | $-9.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Whitehawk Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30353696200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $16.00K | 0.03% |
| Other Components | $385.11 Million | 733.86% |
| Total Equity | $52.48 Million | 100.00% |
Whitehawk Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Whitehawk Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kyungin Synthe
KO:012610
|
$141.43 Million |
|
Journey Medical Corp
NASDAQ:DERM
|
$141.46 Million |
|
Seoho Electric Co.Ltd
KQ:065710
|
$141.49 Million |
|
Iljin Diamond
KO:081000
|
$141.54 Million |
|
Protech Mitra Perkasa Tbk PT
JK:OASA
|
$141.33 Million |
|
Mondi Turkey Oluklui Mukavva Kagit ve Ambalaj Sanayi A.S.
IS:MNDTR
|
$141.21 Million |
|
MNtech Co. Ltd
KQ:095500
|
$141.11 Million |
|
Zapata Computing Holdings Inc. Common Stock
NASDAQ:ZPTA
|
$141.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Whitehawk Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 105,195,000 to 52,478,000, a change of -52,717,000 (-50.1%).
- Net loss of 63,691,000 reduced equity.
- Other comprehensive income decreased equity by 11,000.
- Other factors increased equity by 10,985,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-63.69 Million | -121.37% |
| Other Comprehensive Income | $-11.00K | -0.02% |
| Other Changes | $10.98 Million | +20.93% |
| Total Change | $- | -50.11% |
Book Value vs Market Value Analysis
This analysis compares Whitehawk Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-1.13 | $3.99 | x |
| 2020-12-31 | $-0.71 | $3.99 | x |
| 2021-12-31 | $15.29 | $3.99 | x |
| 2022-12-31 | $7.04 | $3.99 | x |
| 2023-12-31 | $3.91 | $3.99 | x |
| 2024-12-31 | $1.94 | $3.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Whitehawk Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -121.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -245.13%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.34x
- Recent ROE (-121.37%) is below the historical average (-50.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -1636.19% | 0.04x | 0.00x | $-11.35 Million |
| 2020 | 0.00% | -23.85% | 0.77x | 0.00x | $-2.23 Million |
| 2021 | -80.71% | -9829.46% | 0.01x | 1.16x | $-123.73 Million |
| 2022 | -38.21% | -397.69% | 0.08x | 1.16x | $-76.35 Million |
| 2023 | -62.52% | -270.04% | 0.18x | 1.26x | $-76.28 Million |
| 2024 | -121.37% | -245.13% | 0.37x | 1.34x | $-68.94 Million |
Industry Comparison
This section compares Whitehawk Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | $157.17 Million | 0.00% | 0.06x | $141.39 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more